Bladder Cancer

"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.

At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.

The immunotherapy Bavencio improves survival when given as a maintenance treatment in patients whose advanced urothelial carcinoma did not progress on platinum-based chemotherapy.

COVID-19 has drastically changed the landscape for patients with bladder cancer, but the new challenges are not insurmountable. CURE had the chance to interview the co-founder of the Bladder Cancer Advocacy Network to discuss these changes.

Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.

Understanding bladder cancer.

The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.

Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.

Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.

Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.

A new study links e-cigarette use to bladder cancer but experts say more research is needed.

There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.

Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.

The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.

A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.

Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.

The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.

FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.

This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.

At 15 years old the Bladder Cancer Advocacy Network looks back and takes a look ahead.

The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.

The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.